Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Ibrutinib
Related studies linked through entity extraction aliases.
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Inhibition of Anaphylaxis by Ibrutinib
- Status
- COMPLETED
- Phase
- PHASE2
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis
- Status
- WITHDRAWN
- Phase
- PHASE2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- Status
- RECRUITING
- Phase
- PHASE2
Ibrutinib, Nivolumab and Blinatumomab in Richter Transformation
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)
- Status
- COMPLETED
- Phase
- PHASE3
Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)
- Status
- COMPLETED
- Phase
- PHASE3
Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant
- Status
- TERMINATED
- Phase
- PHASE1
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers
- Status
- UNKNOWN
- Phase
- PHASE3
Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy
- Status
- TERMINATED
- Phase
- EARLY_PHASE1
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
- Status
- COMPLETED
- Phase
- PHASE3